Last reviewed · How we verify

ACP-204 — Competitive Intelligence Brief

ACP-204 (ACP-204) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscarinic M1 receptor agonist. Area: Psychiatry / Neurology.

phase 3 Muscarinic M1 receptor agonist M1 muscarinic acetylcholine receptor Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ACP-204 (ACP-204) — ACADIA Pharmaceuticals Inc.. ACP-204 is a muscarinic M1 receptor agonist that enhances cholinergic neurotransmission to improve cognitive and psychiatric symptoms.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ACP-204 TARGET ACP-204 ACADIA Pharmaceuticals Inc. phase 3 Muscarinic M1 receptor agonist M1 muscarinic acetylcholine receptor
ALKS 2680 Dose 1 ALKS 2680 Dose 1 Alkermes, Inc. phase 3 Muscarinic M1 receptor partial agonist M1 muscarinic acetylcholine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscarinic M1 receptor agonist class)

  1. ACADIA Pharmaceuticals Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACP-204 — Competitive Intelligence Brief. https://druglandscape.com/ci/acp-204. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: